Diphencyprone 4% in acetone liquid
Requires a prescription from a doctor or prescriber
Diphencyprone has been used in trials studying the treatment and basic science of Melanoma, Ultraviolet Rays, Immunosuppression, Neoplasm Metastasis, and Hypersensitivity, Delayed, among others.
Shortage warning
Current supply issues
High shortage warning
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
Affected areas: UK
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 7 · Trials: 1 · 1983–2026
Showing the 50 most relevant studies, sorted by most relevant.
Pham JP, Dwyer L, Phan K, et al.
2023
- Melanoma
- Skin Neoplasms
- Cyclopropanes
Charussri Leeyaphan, Ploypailin Tantrapornpong, Patompong Ungprasert
Journal of Dermatological Treatment, 2019
- Warts
- Cryotherapy
- Cyclopropanes
Matheus de Melo Lobo, Vinícius F. Calsavara, Bruno Vita Ricci, et al.
Journal of the American Academy of Dermatology, 2020
- Administration, Cutaneous
- Cyclopropanes
- Haptens
Rudolf Happle, B. M. Hausen, L. Wiesner-Menzel
Acta Dermato Venereologica, 1983
D. Damian, R. Saw, John F. Thompson
Journal of Surgical Oncology, 2014
- Administration, Topical
- Cyclopropanes
- Dermatitis, Contact
Marni Wiseman, Jerry Shapiro, Nina MacDonald, et al.
PubMed, 2001
- Immunotherapy
- Alopecia Areata
- Cyclopropanes
Ruth C. Lamb, David Young, Simon Holmes
Clinical and Experimental Dermatology, 2015
- Lymphadenopathy
- Acne Vulgaris
- Administration, Topical
Ibrahim A. Aljuffali, Calvin T. Sung, Fengming Shen, et al.
The AAPS Journal, 2013
- Cells, Cultured
- Cyclopropanes
- Drug Carriers
Beatrice Pollock, AS Highet
Journal of Dermatological Treatment, 2002
- Cyclopropanes
- Dermatologic Agents
- Facial Dermatoses
S. MACDONALD HULL, Linda Pepall, W.J. Cunliffe
British Journal of Dermatology, 1991
- Allergens
- Alopecia Areata
- Cyclopropanes
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Diphencyprone
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q5279743), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.